GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has announced the closure of its trading window from Tuesday, 1st July 2025 to Wednesday, 6th August 2025, in line with SEBI's insider trading regulations. This means that designated insiders—including directors, officers, and certain employees—will not be allowed to buy or sell the company's shares during this period. The trading window is being closed because the company's Board of Directors is scheduled to meet on Friday, 1st August 2025 to approve and declare the unaudited financial results for the first quarter ended 30th June 2025. The window will reopen 48 hours after the results are announced.
This is a routine regulatory compliance announcement and does not directly affect retail investors or the stock price. However, it signals that the Q1 FY26 earnings announcement is coming up on 1st August 2025, which is the next key event for shareholders to watch.